Table Graph
   

neutralizing antibody - versus control - for COVID-19 prophylaxis (excluding children) pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.87 [0.31, 2.41]< 10%2 studies (2/-)60.5 %some concernnot evaluable moderatecrucial-
hospitalization 0.04 [0.00, 0.63]< 10%1 study (1/-)98.8 %NAnot evaluable important-
symptomatic Covid-19 0.19 [0.12, 0.33]< 10%2 studies (2/-)100.0 %some concernnot evaluable moderateimportant-
infection (PCR positive symptomatic or not) 0.43 [0.28, 0.67]< 10%1 study (1/-)100.0 %NAnot evaluable non important-
severe COVID-19 occurrence 0.25 [0.01, 7.50]< 10%1 study (1/-)78.4 %NAnot evaluable non important-

safety endpoints 00

serious adverse events 2.97 [1.75, 5.03]< 10%1 study (1/-)0.0 %NAnot evaluable important-
adverse events 1.11 [0.35, 3.53]< 198%2 studies (2/-)42.8 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons